FDA Orange Book · active-ingredient family
Pemetrexed
Pemetrexed is approved in 2 FDA applications, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:PEMETREXED · NDA 208419
2
Brand (NDA)
0
Generics (ANDA)
3
Listed patents
0
Exclusivity periods
Brand (NDA) products · solution
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| PEMETREXEDRLD×3 | ACTAVIS | NDA 208419 | — | Aug 21, 2020 | |
| PEMFEXYRLD | EAGLE PHARMS | NDA 209472 | — | Feb 08, 2020 |
Listed patents (3)
| Patent | Expires | In | Type |
|---|---|---|---|
| 9604990 | Oct 28, 2035 | in 9 yr 6 mo | Substance |
| 12115164 | Feb 19, 2036 | in 9 yr 10 mo | U-4246 |
| 11793813 | Feb 19, 2036 | in 9 yr 10 mo | Product |
Pemetrexed — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
